Asciminib vs bosutinib in CML patients pretreated with ≥2 tyrosine kinase inhibitors: Results from the Japanese subgroup analysis of ASCEMBL study-Reference-Cited by-同舟云学术

Asciminib vs bosutinib in CML patients pretreated with ≥2 tyrosine kinase inhibitors: Results from the Japanese subgroup analysis of ASCEMBL study

Published:2022-09-27 Issue:3 Volume:12 Page:2990-2998
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Medicine

Author:

Yuda Junichiro¹,Doki Noriko²,Matsuoka Hiroshi³,Yokota Takafumi⁴,Tomita Akihiro⁵,Takahashi Naoto⁶,Matsumura Itaru⁷,Kubo Kohmei⁸,Goto Tatsunori⁹,Kirito Keita¹⁰,Maki Akio¹¹,Aoki Makoto¹¹,Allepuz Alex¹²,Minami Yosuke¹

Affiliation:

1. National Cancer Center Hospital East Chiba Japan

2. Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital Tokyo Japan

3. Kobe University Hospital Kobe Japan

4. Osaka University Hospital Osaka Japan

5. Fujita Health University School of Medicine Toyoake Japan

6. Akita University Hospital Akita Japan

7. Kindai University Hospital Osaka Japan

8. Aomori Prefectural Central Hospital Aomori Japan

9. Japanese Red Cross Aichi Medical Center Nagoya Daiichi Hospital Nagoya Japan

10. University of Yamanashi Hospital Yamanashi Japan

11. Novartis Pharma KK Tokyo Japan

12. Novartis Pharma AG Basel Switzerland

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.5212

Reference33 articles.

1. The Biology of Chronic Myeloid Leukemia

2. The Philadelphia chromosome in leukemogenesis

3. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013

4. Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology

5. Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-World Disproportionality Analysis of the Food and Drug Administration Adverse Event Reporting System Database for Asciminib;Oncology;2024-08-05

2. Asciminib in Patients With CML-CP Previously Treated With ≥ 2 Tyrosine Kinase Inhibitors: 96-Week Results From the Japanese Subgroup Analysis of the ASCEMBL Study;International Journal of Hematology;2024-06-18

3. Chronisch myeloische Leukämie;DMW - Deutsche Medizinische Wochenschrift;2023-05-31

4. The EMA Assessment of Asciminib for the Treatment of Adult Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase Who Were Previously Treated With at Least Two Tyrosine Kinase Inhibitors;The Oncologist;2023-05-04

5. Pharmacological and clinical profile of asciminib hydrochloride, a novel first-in-class tyrosine kinase inhibitor specifically targeting ABL myristoyl pocket;Folia Pharmacologica Japonica;2023-05-01